Histology of pediatric classic Hodgkin lymphoma: From diagnosis to prognostic stratification.
aberrant phenotype
classic Hodgkin lymphoma
histology
pediatric lymphoma
prognosis
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
09
01
2020
revised:
06
02
2020
accepted:
09
02
2020
pubmed:
7
3
2020
medline:
14
7
2020
entrez:
6
3
2020
Statut:
ppublish
Résumé
Classic Hodgkin lymphoma (cHL) is a common malignancy of the pediatric age. Although clinical-radiological features are routinely used for disease risk stratification, the role of tumor histology has yet to be defined. This study aimed to characterize the clinical-pathological features of a large cohort of pediatric cHL specifically investigating the relevance of tumor histology for the prognostic stratification of patients. The study considered 96 clinically annotated cases of pediatric cHL treated according to the AIEOP-LH2004 protocol. The following histological parameters were considered: (i) cHL variant; (ii) grade of nodular sclerosis (NS); (iii) staining for Bcl2 and p53, and expression of B-cell (BCA) and T-cell antigens (TCA) by Hodgkin/Reed-Sternberg cells. The study population consisted of 51 males and 45 females (median age: 13.6 years) with five-year overall and progression-free survival of 94% and 81%, respectively. Most cases featured NS morphology (96%) with a prevalence of NS1 over NS2 grades. Two NS2 variants were recognized (sarcomatous/syncytial and fibrohistiocytic). A consistent subset of cases disclosed positivity for BCA (34%), TCA (26%), p53 (13%), and Bcl2 (19%). Clinical-pathological correlations showed a more aggressive clinical course for NS2 over NS1 cases. The NS2 fibrohistiocytic variant was associated with the worst outcome. No other histological features correlated with prognosis. Pediatric cHL is a clinically and histologically heterogeneous neoplasm. The majority of cases disclose NS morphology and aberrant phenotypes are frequently encountered. In the pediatric population, NS grading and NS2 subtyping bear significant prognostic impact.
Substances chimiques
Neoplasm Proteins
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28230Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Group AW, Ccm, Group AW. Italian cancer figures, report 2012: cancer in children and adolescents. Epidemiol Prev. 2013;37(1 Suppl 1):1-225.
Xavier AC, Epperla N, Taub JW, et al. Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. Am J Hematol. 2018;93(2):238-245.
Englund A, Hopstadius C, Enblad G, et al. Hodgkin lymphoma-a survey of children and adolescents treated in Sweden 1985-2009. Acta Oncol. 2015;54(1):41-48.
Farruggia P, Puccio G, Sala A, et al. The prognostic value of biological markers in paediatric Hodgkin lymphoma. Eur J Cancer 2016;52:33-40.
Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol. 2003;21(10):2026-2033.
Schwartz CL, Chen L, McCarten K, et al. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2017;64(4). DOI: 10.1002/pbc.26278.
Tubiana M, Henry-Amar M, Burgers MV, et al. Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease. J Clin Oncol. 1984;2(3):194-200.
Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015;125(7):1061-1072.
Kushekhar K, van den Berg A, Nolte I, et al. Genetic associations in classical Hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2737-2747.
Barros MH, Hassan R, Niedobitek G. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res. 2012;18(14):3762-3771.
Guo B, Cen H, Tan X, et al. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Med. 2016;14(1):159.
Swerdlow SH, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017. 585 pp.
MacLennan KA, Bennett MH, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 1989;64(8):1686-1693.
Allemani C, Sant M, De Angelis R, et al. Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 2006;107(2):352-360.
Venkataraman G, Mirza MK, Eichenauer DA, et al. Current status of prognostication in classical Hodgkin lymphoma. Br J Haematol. 2014;165(3):287-299.
Venkataraman G, Song JY, Tzankov A, et al. Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. Blood 2013;121(10):1795-1804.
Pizzi M, Agostinelli C, Righi S, et al. Aberrant expression of CD10 and BCL6 in mantle cell lymphoma. Histopathology 2017;71(5):769-777.
Tzankov A, Bourgau C, Kaiser A, et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol. 2005;18(12):1542-1549.
Sup SJ, Alemany CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol. 2005;23(16):3773-3779.
Chabay P, Pesce P, De Matteo E, et al. No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas. J Pediatr Hematol Oncol. 2006;28(9):552-558.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972;135:185-198.
Cox DR. Regression models and life tables. J R Stat Soc A 1972;34:187-220.
Kahn JM, Ozuah NW, Dunleavy K, et al. Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. Blood Adv. 2017;1(22):1945-1958.
von Wasielewski S, Franklin J, Fischer R, et al. Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages. Blood 2003;101(10):4063-4069.
d'Amore ES, Lee CK, Aeppli DM, et al. Lack of prognostic value of histopathologic parameters in Hodgkin's disease, nodular sclerosis type. A study of 123 patients with limited stage disease who had undergone laparotomy and were treated with radiation therapy. Arch Pathol Lab Med. 1992;116(8):856-861.
Masih AS, Weisenburger DD, Vose JM, et al. Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's disease. Cancer 1992;69(1):228-232.
Makepeace AR, Maclennan KA, Hudson GV, et al. Hodgkin's disease in childhood: the British National Lymphoma Investigation experience (BNLI Report No 27). Clin Radiol. 1987;38(1):7-11.
Wijlhuizen TJ, Vrints LW, Jairam R, et al. Grades of nodular sclerosis (NSI-NSII) in Hodgkin's disease. Are they of independent prognostic value? Cancer 1989;63(6):1150-1153.
Ferry JA, Linggood RM, Convery KM, et al. Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer 1993;71(2):457-463.
Sethi T, Nguyen V, Li S, et al. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Ther Adv Hematol. 2017;8(1):13-20.
Darabi K, Tester, W., Daskal, I. and Cohn, J. Syncytial variant of nodular sclerosing Hodgkin's disease. Blood 2015;104:4533.
Asano N, Oshiro A, Matsuo K, et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study. J Clin Oncol. 2006;24(28):4626-4633.
Hess JL, Bodis S, Pinkus G, et al. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 1994;74(2):708-714.
van Spronsen DJ, Vrints LW, Hofstra G, et al. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92. Br J Haematol. 1997;96(2):322-327.
Tzankov A, Krugmann J, Fend F, et al. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clin Cancer Res. 2003;9(4):1381-1386.
Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20(5):1278-1287.
Tzankov A, Zimpfer A, Pehrs AC, et al. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol. 2003;16(11):1141-1147.
Liang K, Wang J, Wang Y, et al. The histologic, immunohistochemical, and genetic features of classical Hodgkin lymphoma and anaplastic large cell lymphoma with aberrant T-cell/B-cell antigen expression. Hum Pathol. 2019;84:309-320.
Portlock CS, Donnelly GB, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004;125(6):701-708.
Benharroch D, Nalbandyan K, Lazarev I. CD20 over-expression in Hodgkin-Reed-Sternberg cells of classical Hodgkin lymphoma: the neglected quest. J Cancer 2015;6(11):1155-1159.
Elsayed AA, Asano N, Ohshima K, et al. Prognostic significance of CD20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: a clinicopathologic study. Pathol Int. 2014;64(7):336-345.
Canioni D, Deau-Fischer B, Taupin P, et al. Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One 2009;4(7):e6341.
Smolewski P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6(3):1150-1160.
Brink AA, Oudejans JJ, van den Brule AJ, et al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol. 1998;11(4):376-383.
Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997;90(6):2429-2436.
Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100(12):3935-3941.
Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101(2):681-689.
Montalban C, Garcia JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004;22(9):1664-1673.